NMS · Financial Statements

Design Therapeutics, Inc. (DSGN) Financial Statements

$10.24 NMS: DSGN Market Cap $640.84M

Design Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $70.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Design Therapeutics, Inc.: net profit was positive in 0 of 7 reported years; the most recent year shows a net loss of $70.0M.

Income Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Revenue$0$0$0$0$0$0$0
Operating Expenses$2.0M$9.0M$36.0M$68.0M$78.0M$62.0M$79.0M
Operating Profit$-2.0M$-9.0M$-36.0M$-68.0M$-78.0M$-62.0M$-79.0M
Operating Margin-228777.0%0.0%0.0%0.0%0.0%0.0%0.0%
Other Income$0$0$0$4.0M$11.0M$13.0M$10.0M
Interest$0$0$0$0$0$0$0
Depreciation$2.0M$0$0$0$1.0M$1.0M$1.0M
Profit Before Tax$-2.0M$-8.0M$-36.0M$-63.0M$-67.0M$-50.0M$-70.0M
Tax$0$0$0$0$0$0$0
Net Profit$-2.0M$-8.0M$-36.0M$-63.0M$-67.0M$-50.0M$-70.0M
EPS$-0.08$-0.30$-0.77$-1.14$-1.19$-0.88$-1.22
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$19.0M$15.0M$14.0M$15.0M$16.0M$17.0M$20.0M$22.0M$19.0M$18.0M$20.0M$22.0M
Operating Profit$-19.0M$-15.0M$-14.0M$-15.0M$-16.0M$-17.0M$-20.0M$-22.0M$-19.0M$-18.0M$-20.0M$-22.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-16.0M$-12.0M$-11.0M$-12.0M$-13.0M$-14.0M$-18.0M$-19.0M$-17.0M$-16.0M$-18.0M$-20.0M
Tax$0$0$0$0$0$0$0$0$0$0$0$0
Net Profit$-16.0M$-12.0M$-11.0M$-12.0M$-13.0M$-14.0M$-18.0M$-19.0M$-17.0M$-16.0M$-18.0M$-20.0M
EPS$-0.28$-0.21$-0.20$-0.21$-0.23$-0.24$-0.31$-0.34$-0.30$-0.27$-0.29$-0.32

Over the 7 years reported for Design Therapeutics, Inc., borrowings increased from $1.0M in 2019 to $2.0M in 2025, cash stood at $17.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 17.23 times.

Balance Sheet — 7 Years (USD millions)

Metric2019202020212022202320242025
Total Assets$0$37.0M$391.0M$341.0M$290.0M$252.0M$226.0M
Current Assets$0$36.0M$385.0M$335.0M$285.0M$248.0M$224.0M
Cash$0$2.0M$299.0M$27.0M$21.0M$23.0M$17.0M
Inventory$0$0$0$0$0$0$0
Receivables$0$0$0$1.0M$1.0M$1.0M$2.0M
Fixed Assets$0$0$5.0M$6.0M$5.0M$4.0M$2.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments$0$34.0M$85.0M$304.0M$261.0M$223.0M$203.0M
Other Assets$0$0$0$0$0$0$0
Total Liabilities$4.0M$48.0M$8.0M$14.0M$12.0M$10.0M$14.0M
Current Liabilities$4.0M$2.0M$5.0M$11.0M$10.0M$8.0M$13.0M
Borrowings$1.0M$0$4.0M$4.0M$3.0M$2.0M$2.0M
Other Liabilities$3.0M$48.0M$5.0M$10.0M$9.0M$8.0M$12.0M
Equity$0$0$0$0$0$0$0
Reserves$-4.0M$-11.0M$382.0M$327.0M$278.0M$242.0M$213.0M

For Design Therapeutics, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $55.0M; free cash flow was positive in 0 of 7 years.

Cash Flow Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Operating Cash Flow$0$-9.0M$-29.0M$-51.0M$-59.0M$-43.0M$-54.0M
Investing Cash Flow$0$-34.0M$-55.0M$-222.0M$52.0M$44.0M$23.0M
Financing Cash Flow$0$0$0$0$0$0$0
Net Cash Flow$0$2.0M$296.0M$-272.0M$-5.0M$1.0M$-6.0M
Free Cash Flow$0$-9.0M$-31.0M$-52.0M$-59.0M$-43.0M$-55.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.88
EV / EBITDA-10.53
FCF Yield-7.15%
Quick Ratio18.86
Interest Coverage—
Return 1Y172.37%
Return 3Y62.66%
Return 5Y-23.55%

Design Therapeutics, Inc. (DSGN) financials — frequently asked questions

What is Design Therapeutics, Inc.'s annual revenue?

Design Therapeutics, Inc. (DSGN) reported annual revenue of $0 in its most recent fiscal year.

What is Design Therapeutics, Inc.'s net profit?

Design Therapeutics, Inc. (DSGN) reported a net loss of $70.0M in its most recent fiscal year.

What is DSGN EV/EBITDA?

Design Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -10.53. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
DSGN Overview DSGN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.